Articles from Element Biosciences, Inc.

Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced that Madhuri Hegde, Ph.D., has joined its board of directors. Dr. Hegde currently serves as senior vice president and Chief Scientific Officer at Revvity, Inc., where she leads the strategic scientific direction of the company. A board-certified diplomate in clinical molecular genetics from the American Board of Medical Genetics and Genomics (ABMGG), Dr. Hegde brings an incredible depth of experience that will shape Element’s growth and trajectory.

Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the first intelligent multiomics system. Direct in sample sequencing, or DISS, is a high-demand and transformative technology that unlocks unprecedented research possibilities across a variety of new use cases, including lineage tracing and CRISPR screens with simultaneous optical phenotyping, targeted RNA sequencing, custom protein analysis, and more – all completely library-prep free. Direct in sample sequencing technology will be available for preorder May 21, 2025.

Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the Innovation Roadmap for AVITI24,™ the world's first natively paired spatial multiomic solution. The roadmap is being unveiled during an exclusive webinar, titled “High Dimensional Biology Unlocked,” and spearheads Element’s attendance at AGBT 2025 in Marco Island, Florida from February 23-26.

Element Biosciences, Inc., a developer of pioneering technologies to empower science, today announced that Element CEO and co-founder Molly He will be presenting a corporate update at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place at 8:30am PT on Monday, January 13, 2025, at The Westin St. Francis Hotel.

Element Biosciences, Inc., a developer of pioneering technologies to empower science, today introduced Trinity™ - an innovative solution that simplifies target capture sequencing by eliminating or moving traditionally time-consuming steps to the AVITI™ System and providing customers with the option to dramatically reduce hybridization time, without sacrificing cost or quality.

Element Biosciences, Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced it has shipped multiple AVITI systems to its first set of customers. Additionally, Element is introducing new volume-based pricing, launching ElemBio Capital Solutions™ for financing and leasing options, and announcing the upcoming launch of its new AVITI 150-Cycle Sequencing Kit to ship Q4 2022. This is all to meet rapidly growing customer demand following the commercial launch of the AVITI System in March. The details of Element’s newest customers, offerings, and pricing were shared earlier today at the “Elements of Freedom” workshop during the 2022 AGBT General Meeting.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Dovetail Genomics demonstrating the value and performance of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI System.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a collaboration and co-marketing partnership with Jumpcode Genomics that validates Jumpcode's CRISPRclean technology on Element’s AVITI System. The partnership has already demonstrated the value of pairing the technologies, promising improved data quality and cost savings across various genomic applications.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a key technical milestone using the Roche KAPA HyperPlus and KAPA EvoPlus library preparation and target enrichment kits in microbial whole genome, human whole genome, and human whole exome sequencing applications.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with New England Biolabs (NEB®) to commercially develop and launch products to enable compatibility of the NEBNext Ultra II portfolio with the Element AVITI System.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System. This partnership demonstrates compatibility of the Element AVITI System’s performance, cost and flexibility with a selection of QIAGEN’s most popular QIAseq target enrichment panels.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Watchmaker Genomics demonstrating the value and performance of Watchmaker’s DNA and RNA Library Prep Kits on Element’s AVITI System.